TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12324553

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a plus ribavirin (180 microg once weekly + daily ribavirin 1000 or 1200 mg)
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Interferon alfa‐2b plus ribavirin (3 million units thrice weekly + daily ribavirin)
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Peginterferon alfa‐2a alone (weekly peginterferon alfa‐2a + daily placebo)
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Patients with HCV genotype 1 receiving peginterferon alfa‐2a plus ribavirin
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Patients with HCV genotype 1 receiving interferon alfa‐2b plus ribavirin
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Patients with HCV genotype 1 receiving peginterferon alfa‐2a alone
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Patients with HCV genotype 1 and high baseline levels of HCV RNA receiving peginterferon alfa‐2a plus ribavirin
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Patients with HCV genotype 1 and high baseline levels of HCV RNA receiving interferon alfa‐2b plus ribavirin
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Patients with HCV genotype 1 and high baseline levels of HCV RNA receiving peginterferon alfa‐2a alone
Number of subjects: 1121
Study: 9665239

Group type: EXPERIMENTAL
Intervention: DHE-PDT (4.25 mg/kg)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: DHE-PDT (3.25 mg/kg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (conventional therapy)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: DHE-PDT
Number of subjects: 81
Study: 8607303

Group type: EXPERIMENTAL
Intervention: EMLA cream applied 10 to 120 minutes before heel-lancing
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo applied 10 to 120 minutes before heel-lancing
Number of subjects: 112
Study: 2590615

Group type: EXPERIMENTAL
Intervention: 20 mg 'biphasic' nifedipine taken 12 hourly for 10 days
Number of subjects: 15
Study: 811074

Group type: EXPERIMENTAL
Intervention: Carbamazepine (C)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 23
Study: 31230016

Group type: EXPERIMENTAL
Intervention: Ropivacaine plus Methylprednisolone (RP/MP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ropivacaine alone (RP)
Number of subjects: 100
Study: 28902084

Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy (4 courses for LR, 6 courses for IR and HR) followed by restricted radiotherapy (RT) if partial remission. Low-dose involved field radiotherapy: 21 Gy plus 14 Gy boost for residual disease.
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy (6 courses) followed by 21 Gy involved field radiotherapy for HR patients achieving CR.
Number of subjects: 165
Study: 24711637

Group type: COMPARATOR
Intervention: Conventional PD solution
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Biocompatible PD solution
Number of subjects: 50
Study: 23873545

Group type: EXPERIMENTAL
Intervention: Infected group (challenged with 10(5) ELD50/0.1 mL of infectious bronchitis virus)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (clinically healthy chicks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Infected group
Number of subjects: 90
Study: 21318563

Group type: EXPERIMENTAL
Intervention: Nicotine Cannon (NC)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Nicotine Cannon (NC) and mini-lozenge
Number of subjects: 196
Study: 19703383

Group type: EXPERIMENTAL
Intervention: Psycho-educational, coping-oriented therapy programme (PKB)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Supportive dialogues or occupational rehabilitation programme
Number of subjects: 82
Study: 17867915

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 20479

Group type: EXPERIMENTAL
Intervention: Enoxaparin (novel dosing for elderly patients)
Number of subjects: 20479

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 20479
Study: 15090125

Group type: EXPERIMENTAL
Intervention: Attaining more fruit-juice goals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attaining one vegetable goal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attaining three general goals
Number of subjects: 0
Study: 11701711

Group type: EXPERIMENTAL
Intervention: GH treatment for 6 days
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: IGF-I treatment for 6 days
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: GH treatment in GHD patients
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Octreotide or pegvisomant treatment in acromegalic patients for 3 months
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control period (no treatment)
Number of subjects: 94
Study: 9219043

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg once a day) plus Pindolol (2.5 mg three times a day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Paroxetine (20 mg once a day) plus Placebo
Number of subjects: 80
Study: 8279647

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) 6 mg/kg one time or 1 mg/kg, then 6 mg/kg four days later
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ivermectin 220 micrograms/kg; 20 micrograms/kg, then 200 micrograms/kg four days later or 20 micrograms/kg, then 400 micrograms/kg four days later
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) or 420 micrograms/kg of ivermectin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Single-dose DEC
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ivermectin groups
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study: 3735143

Group type: EXPERIMENTAL
Intervention: Individual gambling
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Group gambling
Number of subjects: 38
Study: 30293166

Group type: EXPERIMENTAL
Intervention: Force of the stream (FOS)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard voiding trial (SVT)
Number of subjects: 102
Study: 29779816

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (6 capsules daily, each containing 180 mg EPA and 120 mg DHA)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (6 capsules daily)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 27756434

Group type: EXPERIMENTAL
Intervention: T3 intervention (evidence-based care bundle)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control EDs (no additional support)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T3 intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control EDs
Number of subjects: 0
Study: 24702577

Group type: EXPERIMENTAL
Intervention: MMC-PRK
Number of subjects: 167

Group type: COMPARATOR
Intervention: PRK
Number of subjects: 167

Group type: COMPARATOR
Intervention: LASEK
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: PRK, LASEK, MMC-PRK
Number of subjects: 167
Study: 22362836

Group type: EXPERIMENTAL
Intervention: Videoconferencing (VC) administration of RUDAS
Number of subjects: 42

Group type: COMPARATOR
Intervention: Face-to-face (FTF) administration of RUDAS
Number of subjects: 42
Study: 20409200

Group type: EXPERIMENTAL
Intervention: Extraction of two deciduous canines
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Extraction of four deciduous canines
Number of subjects: 32
Study: 17431619

Group type: EXPERIMENTAL
Intervention: Patellar tendon autograft
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Hamstring tendon autograft
Number of subjects: 64
Study: 16213029

Group type: EXPERIMENTAL
Intervention: Any abuse (AA)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Combined abuse (CA)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Sexual abuse without physical abuse (SA)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Physical abuse without sexual abuse (PA)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Younger age at study entry
Number of subjects: 330
Study: 12198057

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg IV
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10203371

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO) therapy
Number of subjects: 7
Study: 7758177

Group type: COMPARATOR
Intervention: TPA 100 mg i.v. over 3 hours
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: r-PA 15-MU single bolus
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: r-PA 10-MU bolus followed by 5 MU 30 minutes later
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: r-PA 10-MU bolus followed by 10 MU 30 minutes later
Number of subjects: 606
Study: 2135709

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 5
Study: 43966

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg, oral application)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Carazolol (5 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propranolol and Carazolol
Number of subjects: 40
Study: 30756456

Group type: EXPERIMENTAL
Intervention: T2*‐weighted (T2*W) MRI
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: T2‐weighted (T2W) MRI
Number of subjects: 10

Group type: COMPARATOR
Intervention: CT imaging
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Geometric assessment using MRI
Number of subjects: 10
Study: 28420105

Group type: EXPERIMENTAL
Intervention: Synthetic intervention for 1 year
Number of subjects: 434

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 434
Study: 25920801

Group type: EXPERIMENTAL
Intervention: Brief drinking interventions (varied in intensity over 60 days)
Number of subjects: 254
Study: 23511704

Group type: EXPERIMENTAL
Intervention: Isoflavones (100-200 mg daily)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Twice-daily to thrice-daily dosing frequency of isoflavones
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Equol producers
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Equol nonproducers
Number of subjects: 130
Study: 21192296

Group type: EXPERIMENTAL
Intervention: Therapeutic climbing
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard exercise therapy
Number of subjects: 28
Study: 19143531

Group type: EXPERIMENTAL
Intervention: Omeprazole coadministration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Raltegravir
Number of subjects: 0
Study: 17097031

Group type: EXPERIMENTAL
Intervention: Tecnis Z9001 intraocular lens
Number of subjects: 20

Group type: COMPARATOR
Intervention: CeeOn 911A intraocular lens
Number of subjects: 20
Study: 15623271

Group type: EXPERIMENTAL
Intervention: Guided Choice
Number of subjects: 2437

Group type: EXPERIMENTAL
Intervention: Informed Choice
Number of subjects: 2437

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 2437
Study: 11239729

Group type: EXPERIMENTAL
Intervention: Skill training program for parents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed treatment condition
Number of subjects: 0
Study: 9865671

Group type: EXPERIMENTAL
Intervention: Omacor (4 g/day for 4 months)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 7940133

Group type: EXPERIMENTAL
Intervention: betaxolol 0.5%
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: timolol 0.5%
Number of subjects: 25
Study: 3219226

Group type: EXPERIMENTAL
Intervention: Immunohistochemical assay for estrogen receptor (ER) status in primary tumors and metastases
Number of subjects: 143
Study: 29476803

Group type: EXPERIMENTAL
Intervention: Water-based combined training (WBC, n=11)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Water-based aerobic training (WBA, n=13)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-periodized physical activity program (CG, n=9)
Number of subjects: 41
Study: 26972925

Group type: EXPERIMENTAL
Intervention: siltuximab plus best supportive care (B.S.C.)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: siltuximab
Number of subjects: 79

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 79
Study: 24918629

Group type: EXPERIMENTAL
Intervention: Low tidal volume with PEEP (6 mL/kg tidal volume, 5 cm H2O PEEP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional ventilation (10 mL/kg tidal volume, 0 cm H2O PEEP)
Number of subjects: 86
Study: 22569835

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day added to interferon beta‐1b
Number of subjects: 77

Group type: COMPARATOR
Intervention: Interferon beta‐1b monotherapy
Number of subjects: 77
Study: 20332266

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (45 minutes, 5 days per week)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control (usual life-style)
Number of subjects: 320
Study: 18525029

Group type: EXPERIMENTAL
Intervention: Low-flow ventriculoperitoneal shunt
Number of subjects: 215

Group type: COMPARATOR
Intervention: Sham (occluded) shunt
Number of subjects: 215
Study: 14749756

Group type: EXPERIMENTAL
Intervention: Biosynthetically labelled trout fish
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Biosynthetically labelled brewers yeast
Number of subjects: 35

Group type: COMPARATOR
Intervention: Isotopically labelled selenate
Number of subjects: 35
Study: 11192305

Group type: EXPERIMENTAL
Intervention: Heparin pretreatment (HP)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Non-heparin pretreatment (NHP)
Number of subjects: 13
Study: 9560837

Group type: EXPERIMENTAL
Intervention: Diet group (4-week regimen with dietary advice on egg exclusion)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (general advice only)
Number of subjects: 55
Study: 7839499

Group type: EXPERIMENTAL
Intervention: Aerobic and anaerobic exercising conditions
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Anaerobic static exercise
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Resting values of Pi/PCr
Number of subjects: 19

Group type: COMPARATOR
Intervention: Pi/PCr and pH changes during work and recovery
Number of subjects: 19
Study: 3066139

Group type: EXPERIMENTAL
Intervention: Nimodipine 2 mg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nimodipine 3 mg/h
Number of subjects: 0
Study: 30594226

Group type: EXPERIMENTAL
Intervention: CaP-hybridized tendon graft method
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 25611962

Group type: EXPERIMENTAL
Intervention: Tadalafil (1 mg/kg daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Transition from sildenafil to tadalafil
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tadalafil administration
Number of subjects: 25
Study: 25649903

Group type: EXPERIMENTAL
Intervention: Laparoscopy with fast-track treatment (LAFT)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Open surgery with fast-track treatment (OSFT)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Laparoscopy with conventional treatment (LAC)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Open surgery with conventional treatment (OSC)
Number of subjects: 92
Study: 22938776

Group type: EXPERIMENTAL
Intervention: Diaphragm training using an adjustable pressure device (Threshold; Philips Respironics Inc)
Number of subjects: 69

Group type: COMPARATOR
Intervention: No training (sham device)
Number of subjects: 69
Study: 20854334

Group type: EXPERIMENTAL
Intervention: CBT4CBT (computerized cognitive behavioral therapy)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 52
Study: 18491421

Group type: EXPERIMENTAL
Intervention: d4T+3TC
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: ZDV+3TC
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: ABC+3TC
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: d4T+3TC and ZDV+3TC
Number of subjects: 308
Study: 17699343

Group type: EXPERIMENTAL
Intervention: Omacor (omega-3 fatty acids)
Number of subjects: 0
Study: 12880608

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (400 ml daily of a supplement enriched with protein, arginine, zinc and antioxidants)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (non-caloric, water-based supplement)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 11082935

Group type: EXPERIMENTAL
Intervention: Anthocyanins administered to 50 women
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo administered to 55 women
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group of 60 healthy pregnant women
Number of subjects: 105
Study: 9361661

Group type: EXPERIMENTAL
Intervention: Telephone Cognitive Assessment Battery (TCAB) administered before in-person assessment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Telephone Cognitive Assessment Battery (TCAB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: In-person assessment
Number of subjects: 80
Study: 1489122

Group type: EXPERIMENTAL
Intervention: Atropine (0.5 mg intranasally)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (intranasally)
Number of subjects: 18
Study: 3986441

Group type: EXPERIMENTAL
Intervention: Bilateral ECT (B/ECT)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Unilateral ECT (U/ECT)
Number of subjects: 37
Study: 31193363

Group type: EXPERIMENTAL
Intervention: Mindfulness based intervention (Learning 2 Breath Mindfulness Curriculum)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Attention intervention
Number of subjects: 23
Study: 28939265

Group type: EXPERIMENTAL
Intervention: comfilcon A lenses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: lotrafilcon A lenses
Number of subjects: 20
Study: 26975720

Group type: EXPERIMENTAL
Intervention: Financial incentive provided to authors (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No financial incentive provided to authors (control group)
Number of subjects: 0
Study: 24221450

Group type: EXPERIMENTAL
Intervention: Pharmacist feedback intervention
Number of subjects: 695

Group type: COMPARATOR
Intervention: Control group (no pharmacist feedback)
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Pharmacist feedback intervention (men)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Control group (men)
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Pharmacist feedback intervention (patients ≥70 years)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Control group (patients ≥70 years)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 695
Study: 22552046

Group type: EXPERIMENTAL
Intervention: Methylphenidate (40 mg)
Number of subjects: 16
Study: 20354453

Group type: COMPARATOR
Intervention: Gemcitabine 1000 mg/m on days 1 and 8 (G)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m on days 1 and 8 plus docetaxel 75 mg/m on day 1 (GD)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus docetaxel (GD)
Number of subjects: 83
Study: 18024211

Group type: EXPERIMENTAL
Intervention: FEC regimen (fluorouracil, epirubicin, and cyclophosphamide for six cycles)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: TET regimen (docetaxel for three cycles followed by epirubicin plus docetaxel for three cycles)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Both regimens (FEC and TET)
Number of subjects: 125
Study: 12633794

Group type: EXPERIMENTAL
Intervention: PMLR with optimal medical therapy (n = 36)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Optimal medical therapy alone (n = 37)
Number of subjects: 73
Study: 10852758

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) plus albuterol
Number of subjects: 180

Group type: COMPARATOR
Intervention: Albuterol plus placebo (control)
Number of subjects: 180
Study: 9235646

Group type: EXPERIMENTAL
Intervention: Lyme arthritis (LA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Reactive arthritis (RA)
Number of subjects: 45
Study: 8261405

Group type: COMPARATOR
Intervention: Oral VP16 daily for up to 21 days (Arm A)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral VP16 daily for up to 21 days plus concomitant GM-CSF at 5 micrograms/kg/day (Arm B)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral VP16 daily for up to 21 days plus pretreatment with GM-CSF (Arm C)
Number of subjects: 31
Study: 3913184

Group type: EXPERIMENTAL
Intervention: Prophylactic coronary bypass surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adequate medical treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary bypass surgery
Number of subjects: 0
Study: 30635781

Group type: EXPERIMENTAL
Intervention: HHT-containing regimens (arm B)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard chemotherapy regimen comprising mainly of anthracyclines and cytarabine (arm A)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 59
Study: 28535639

Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 110

Group type: COMPARATOR
Intervention: Microscopic surgery
Number of subjects: 110
Study: 26423851

Group type: EXPERIMENTAL
Intervention: Health advice from health professionals to avoid constrictive clothing around the trunk along with anaemia prevention leaflets and skin-care leaflets.
Number of subjects: 616

Group type: COMPARATOR
Intervention: Anaemia prevention leaflets and skin-care leaflets.
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Health advice from health professionals to avoid constrictive clothing around the trunk.
Number of subjects: 616
Study: 24171329

Group type: EXPERIMENTAL
Intervention: Intravaginal cleansing in the previous 30 days
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Intravaginal cleansing in the three days before baseline
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Intravaginal cleansing for hygiene unrelated to sex
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Frequency of cleansing
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Products used for washing
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Association with having more than one sex partner in the previous three months
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Association with experiencing itching in the genital area at baseline
Number of subjects: 293
Study: 21329971

Group type: EXPERIMENTAL
Intervention: Vero-cell-culture-derived influenza vaccine
Number of subjects: 7250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7250